Comprehensive, evidence-based information on Retatrutide (LY3437943) — Eli Lilly's investigational triple-agonist GLP-1/GIP/Glucagon receptor drug. Explore clinical trial data, side effect management, dosing guidance, and real-world user experiences.
Browse comprehensive guides covering every aspect of Retatrutide — from how it works to real-world experiences and side effect management.
Understand the science behind Eli Lilly's triple-agonist drug, how it differs from existing GLP-1 treatments, and why researchers are calling it a potential breakthrough in weight management.
ScienceDeep dive into how Retatrutide simultaneously activates three receptor pathways — GLP-1, GIP, and Glucagon — to produce enhanced metabolic effects beyond single or dual agonists.
Clinical DataComprehensive analysis of Phase 2 and Phase 3 TRIUMPH trial data including weight loss outcomes, safety profiles, dosing protocols, and comparison with placebo groups.
SafetyComplete overview of reported side effects from clinical trials — including nausea, GI effects, fatigue, and more — with evidence-based management strategies for each.
ComparisonsHead-to-head comparison of Retatrutide with Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide). Understand the key differences in efficacy, side effects, and mechanism.
Breaking · 21 May 2026Eli Lilly's flagship Phase 3 obesity read-out: 70.3 lbs (31.9 kg) average weight loss at 80 weeks, 30.3% (85 lbs) at 104 weeks in the BMI ≥35 extension, 45.3% of 12-mg participants reaching the bariatric-surgery ≥30% threshold. Full UK guide.
New 2026Lilly's weekly triple agonist (28.7% weight loss in TRIUMPH-4) vs Amgen's monthly GLP-1 / GIP-antagonist bispecific (~20% in Phase 2). Mechanism, dosing, side effects, MARITIME Phase 3 timeline, UK MHRA window.
CommunityReal-world reports from the research community — weight loss results, side effect timelines, dosing experiences, and practical tips shared by those following Retatrutide protocols.
Step-by-step resources for those participating in clinical trials or researching Retatrutide protocols under medical supervision.
Complete guide to pen preparation, injection technique, site rotation, storage requirements, and needle disposal safety protocols.
LifestyleEvidence-based dietary strategies to support your treatment — protein targets, meal timing, hydration, and nutritional priorities during rapid weight loss.
LifestyleOptimise your training alongside Retatrutide treatment. Resistance training guidance, cardio recommendations, and strategies to preserve lean muscle mass.
GuideProper temperature control, refrigeration requirements, travel tips, and shelf life information to maintain medication stability and safety.
FAQAnswers to the most common questions about Retatrutide — from how it works and when it might be approved, to dosing schedules and what to expect.
ArticlesOur complete library of in-depth articles covering side effects, dosing, lifestyle optimisation, drug comparisons, longevity peptides, and more.
Key findings from Retatrutide's clinical trial programme.
The landmark 48-week Phase 2 trial demonstrated up to 24.2% mean body weight loss at the highest dose, with dose-dependent efficacy across all treatment arms.
Phase 3Overview of the ongoing TRIUMPH Phase 3 trial programme including TRIUMPH-1 through TRIUMPH-5, study designs, endpoints, and expected completion timelines.
DataDetailed analysis of weight loss efficacy, metabolic improvements, cardiovascular markers, and comprehensive safety data from all published Retatrutide trials.
TimelineTrack the regulatory pathway for Retatrutide — from Phase 3 trial completion through FDA and EMA review to potential UK NICE approval and NHS availability.
Longevity Research Network
Retatrutide users increasingly combine GLP-1 therapy with broader longevity protocols. Longevity Stack is our sister resource — evidence-graded peptides, supplement stacks, and structured healthspan protocols.
Whether you're new to Retatrutide or looking for specific clinical data, our comprehensive library has you covered.
